Education
About Us
Working with TipRanks
Follow Us
Pharming Group (PHAR)
NASDAQ:PHAR
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 1.44%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Positive
The earnings call was largely positive, with significant revenue growth and successful execution of strategic initiatives. However, challenges such as acquisition-related expenses and increased tax costs were noted.Company Guidance
During the Q1 2025 call, Pharming announced several key metrics and strategic updates that illustrate the company's robust growth and future prospects. The company reported a 42% increase in total revenues, with RUCONEST sales surging 49% to $68.6 million, driven by increased patient enrollment and an expanded prescriber base. Joenja's revenue rose by 9% to $10.5 million, buoyed by new patient enrollments. Pharming upgraded its full-year revenue guidance to between $325 million and $340 million, reflecting a growth range of 9% to 14%. The company also plans to cut G&A expenses by $10 million annually to optimize capital allocation. Additionally, Pharming is advancing its pipeline with initiated Phase II studies for genetic PID and CVID, and it has resumed the enrollment of the Phase II registrational trial for KL1333 in MTD, all of which are expected to significantly expand their market presence. Despite a reported Q1 operating loss, the company maintained a positive operating cash flow for the third consecutive quarter, even after accounting for non-recurring acquisition costs.Impressive Revenue Growth
Total revenues increased by 42% in the first quarter of 2025, driven by a 49% growth in RUCONEST sales.
RUCONEST Strong Performance
RUCONEST sales reached $68.6 million, with a 49% increase year-over-year, driven by new patient enrollment and prescriber expansion.
Joenja Revenue Increase
Joenja revenue increased by 9%, driven by new patient enrollment and expansion into new markets like the U.K.
Operating Loss Narrowing
Operating loss narrowed significantly year-over-year, with a third consecutive quarter of profit, excluding nonrecurring expenses.
Pipeline Progress
Initiation of Phase II studies for genetic PID and CVID, with potential to expand Joenja's patient population significantly.
Financial Guidance Upgrade
Full-year revenue guidance increased to $325 million-$340 million, reflecting a growth of 9%-14%.
---
PHAR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PHAR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $9.00 | $10.01 | +11.22% |
Mar 13, 2025 | $7.74 | $8.74 | +12.92% |
Oct 24, 2024 | $8.96 | $8.30 | -7.37% |
Aug 01, 2024 | $8.33 | $7.63 | -8.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Pharming Group (PHAR) report earnings?
Pharming Group (PHAR) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Pharming Group (PHAR) earnings time?
Pharming Group (PHAR) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PHAR EPS forecast?
PHAR EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.
---